ReviewJournal of pathogens2020
SARS-CoV-2, Early Entry Events.
Review in Journal of pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry.ACS omega · 2025Review
- Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.International journal of molecular sciences · 2024Review
- Article
- Article
- Article
- Assessment of the Prevalence and Incidence of COVID-19 in Saudi Arabia.Journal of multidisciplinary healthcare · 2023Review
- Will Peptides Help to Stop COVID-19?Biochemistry. Biokhimiia · 2022Review
- The Endolysosomal System: The Acid Test for SARS-CoV-2.International journal of molecular sciences · 2022Review
- Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone.Frontiers in pharmacology · 2022Review
- Cetylpyridinium chloride promotes disaggregation of SARS-CoV-2 virus-like particles.Journal of oral microbiology · 2022Article
- COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis.F1000Research · 2022Review
- Spike S1 domain interactome in non-pulmonary systems: A role beyond the receptor recognition.Frontiers in molecular biosciences · 2022Article
- Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System.Stem cell reviews and reports · 2021Review
- Proteases and variants: context matters for SARS-CoV-2 entry assays.Current opinion in virology · 2021Review
- Review
- SARS-CoV-2 biology and variants: anticipation of viral evolution and what needs to be done.Environmental microbiology · 2021Article
- The Role of High-Density Lipoprotein in COVID-19.Frontiers in pharmacology · 2021Review
- A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells.Computational and structural biotechnology journal · 2021Article
- A Review on Expression, Pathological Roles, and Inhibition of TMPRSS2, the Serine Protease Responsible for SARS-CoV-2 Spike Protein Activation.Scientifica · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Viruses are obligate intracellular parasites, and host cell entry is the first step in the viral life cycle. The SARS-CoV-2 (COVID-19) entry process into susceptible host tissue cells is complex requiring (1) attachment of the virus via the conserved spike (S) protein receptor-binding motif (RBM) to the host cell angiotensin-converting-enzyme 2 (ACE2) receptor, (2) S protein proteolytic processing, and (3) membrane fusion. Spike protein processing occurs at two cleavage sites, i.e., S
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.